Zacks Research Issues Optimistic Outlook for BMRN Earnings

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Equities researchers at Zacks Research lifted their Q1 2025 earnings per share (EPS) estimates for shares of BioMarin Pharmaceutical in a research note issued on Tuesday, November 19th. Zacks Research analyst S. Ganoria now forecasts that the biotechnology company will post earnings per share of $0.60 for the quarter, up from their previous estimate of $0.59. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $2.47 per share. Zacks Research also issued estimates for BioMarin Pharmaceutical’s Q2 2025 earnings at $0.68 EPS, Q1 2026 earnings at $0.76 EPS, Q2 2026 earnings at $0.83 EPS and FY2026 earnings at $3.36 EPS.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings results on Tuesday, October 29th. The biotechnology company reported $0.55 EPS for the quarter, missing the consensus estimate of $0.78 by ($0.23). The company had revenue of $746.00 million during the quarter, compared to analysts’ expectations of $703.37 million. BioMarin Pharmaceutical had a return on equity of 8.53% and a net margin of 11.71%. The firm’s revenue for the quarter was up 28.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.26 EPS.

Several other equities research analysts also recently weighed in on the stock. Stifel Nicolaus reduced their target price on shares of BioMarin Pharmaceutical from $115.00 to $87.00 and set a “buy” rating on the stock in a research note on Tuesday, September 17th. Piper Sandler increased their price target on BioMarin Pharmaceutical from $107.00 to $122.00 and gave the stock an “overweight” rating in a research report on Thursday, September 5th. JPMorgan Chase & Co. decreased their price objective on BioMarin Pharmaceutical from $110.00 to $109.00 and set an “overweight” rating for the company in a report on Wednesday, October 30th. Raymond James restated an “outperform” rating and issued a $79.00 price target on shares of BioMarin Pharmaceutical in a report on Thursday, October 10th. Finally, StockNews.com raised shares of BioMarin Pharmaceutical from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Seven analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $94.20.

BioMarin Pharmaceutical Trading Up 1.4 %

Shares of BMRN stock opened at $63.44 on Thursday. The company has a market cap of $12.09 billion, a PE ratio of 37.99, a price-to-earnings-growth ratio of 0.61 and a beta of 0.31. The company has a debt-to-equity ratio of 0.11, a current ratio of 4.27 and a quick ratio of 2.62. The stock’s 50 day simple moving average is $68.67 and its two-hundred day simple moving average is $78.60. BioMarin Pharmaceutical has a 1 year low of $61.15 and a 1 year high of $99.56.

Insider Buying and Selling

In related news, EVP Charles Greg Guyer sold 5,278 shares of the business’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $66.37, for a total transaction of $350,300.86. Following the transaction, the executive vice president now directly owns 68,909 shares in the company, valued at approximately $4,573,490.33. The trade was a 7.11 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 1.85% of the stock is owned by insiders.

Hedge Funds Weigh In On BioMarin Pharmaceutical

A number of institutional investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC acquired a new stake in BioMarin Pharmaceutical during the third quarter worth $809,000. TD Private Client Wealth LLC grew its stake in shares of BioMarin Pharmaceutical by 57.4% in the third quarter. TD Private Client Wealth LLC now owns 510 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 186 shares in the last quarter. Toronto Dominion Bank raised its holdings in shares of BioMarin Pharmaceutical by 31.3% in the 3rd quarter. Toronto Dominion Bank now owns 23,942 shares of the biotechnology company’s stock valued at $1,683,000 after buying an additional 5,711 shares during the period. Neo Ivy Capital Management boosted its holdings in BioMarin Pharmaceutical by 2,225.2% during the 3rd quarter. Neo Ivy Capital Management now owns 21,020 shares of the biotechnology company’s stock valued at $1,478,000 after acquiring an additional 20,116 shares during the period. Finally, Geode Capital Management LLC increased its stake in BioMarin Pharmaceutical by 1.9% during the third quarter. Geode Capital Management LLC now owns 3,260,050 shares of the biotechnology company’s stock worth $228,632,000 after purchasing an additional 60,692 shares during the period. Hedge funds and other institutional investors own 98.71% of the company’s stock.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.